METHOD FOR REPURPOSING NDC CODES IN A PHARMACEUTICAL DATABASE FOR VENOM DERIVED ALLERGENS INVOLVED IN VENOM IMMUNOTHERAPY

• US 20160371445A1
• Filed: 08/11/2016
• Published: 12/22/2016
• Est. Priority Date: 06/02/2015
• Status: Active Grant

• Current Assignee: Avrio Genetics LLC Formerly Procreative LLC
• Original Assignee: Roca Medical Ltd.
• Inventors: STRADER, JAMES, PULITZER, JOVAN HUTTON
• Granted Patent: US 10,872,313 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: G06Q 10/10 Office automation; Time management
• CPC Class Codes: G06Q 40/08 Insurance

Abstract

A method for adjudicating reimbursement for venom derived allergens between a pharmacist and a reimbursing entity comprises obtaining National Drug Codes (NDC'"'"'s) for a plurality of venom derived allergens, storing in a central control database the obtained NDC'"'"'s in association with an associated AWP and associated information for the venom derived allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying venom derived antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying venom derived antigen used to create the desired diluted level and number of doses, and determining if any of the NDC'"'"'s in the central control database are contained within the third-party database and, if not, transferring the associated NDC'"'"'s not in the third-party database to the third-party database.

Claims

1. A method for adjudicating reimbursement for venom derived allergens between a pharmacist and a reimbursing entity, comprising:

obtaining at a central control center National Drug Codes (NDC'"'"'s) for a plurality of venom derived allergens at a defined concentration level, each NDC uniquely identifying that particular allergen as to its manufacture, the particular allergen, the packaging and the defined concentration level, and further obtaining information as to a description of the particular venom derived allergen, concentration level and manufacturer;

determining by the central control center an Average Wholesale Price (AWP) for each of the venom derived allergens associated with each of the NDC'"'"'s;

storing in a central control database the obtained NDC'"'"'s in association with an associated AWP and associated information for the venom derived allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying venom derived antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying venom derived antigen used to create the desired diluted level and number of doses;

accessing a third-party database accessible by a pharmacist and determining if any of the NDC'"'"'s in the central control database are contained within the third-party database and, if not;

transferring the associated NDC'"'"'s not in the third-party database and that exist in the central control database for each of the venom derived allergens to the third-party database in association with the AWP and associated information for each of the venom derived allergens for each of the NDC'"'"'s, and

uniquely associating each of the NDC'"'"'s in the third-party database to the central control center for adjudication information; and

creating an adjudicating database at the central control center having defined benefits associated with reimbursable entities for each of the NDC'"'"'s stored in the third-party database and in the central control database in association with the translation information for each of the NDC-carrying venom derived antigens, wherein a pharmacist can access this information by accessing a particular NDC in the third-party database to obtain information regarding reimbursable benefits from the central control center and enter the diluted level and number of doses and a claim with the central control center for adjudication of the amount of base concentrate venom derived antigen used and wherein the central control center is able to process any claim made by the pharmacist and reimburse the pharmacist accordingly for the base concentrate venom derived antigen used to provide the desired diluted level and number of doses of the desired NDC carrying venom derived antigen.

2. The method of claim 1, wherein the base concentrate NDC-carrying antigen is any concentration level that is too toxic for a patient to be exposed to.

3. The method of claim 1, and further comprising the step of a physician creating a script defining a desired diluted level and number of doses of the desired NDC-carrying venom derived antigen.

4. The method of claim 3, wherein the desired diluted level and number of doses of desired NDC-carrying venom derived antigen includes a script defining a desired level and number of doses of a plurality of NDC-carrying venom derived antigens to be included within each dose.

5. The method of claim 3, and further comprising diluted by a pharmacist the NDC-carrying venom derived antigen to the desired level and number of doses defined by the created script by the physician.

6. The method of claim 1, wherein the translation information includes a table of dilution levels of the NDC-carrying venom derived antigen close the associated with a plurality of dilution procedures wherein each dilution level defines a number of doses at that dilution level and, via the known one of the plurality of dilution procedures, the amount of base concentrate NDC-carrying venom derived antigen required yield that desired dilution level and number of doses.

7. The method of claim 6, wherein each of the NDC-carrying the venom derived antigen is defined as being able to be distributed in discrete quantities, each of the discrete quantities associated with a starting level of NDC-carrying venom derived antigen and each of the discrete quantities adjudicatable.